Domov › Poklici › Biochemists and Biophysicists › San Carlos, CA
Biochemists and Biophysicists v San Carlos, CA: plače H-1B
35 vlog za delovne pogoje za ta poklic z delovnim mestom v San Carlos, CA. Medianna osnovna plača $117.700; srednja polovica $108.750–$165.000.
Po plačilnem razredu
| Raven plače | Mediana plače |
|---|---|
| Stopnja I (začetna) | $90.000 |
| Stopnja II (kvalificirana) | $113.000 |
| Stopnja III (izkušena) | $165.000 |
| Stopnja IV (polno usposobljena) | $174.006 |
Department of Labor določi štiri stopnje prevladujočih plač za vsak poklic in območje, od Stopnje I (začetna) do Stopnje IV (popolna usposobljenost). Delodajalec izbere stopnjo, ki ustreza zahtevam delovnega mesta.
Delodajalci
| Delodajalec | LCA | Mediana plače |
|---|---|---|
| Vaxcyte, Inc. | 19 | $152.300 |
| Nautilus Subsidiary, Inc | 5 | $128.649 |
| Nautilus Biotechnology, Inc. | 2 | $105.000 |
| Synthetic Design Lab, Inc. | 2 | $116.441 |
| LakePharma, Inc. | 1 | $102.000 |
| Nautilus Subsidary, Inc | 1 | — |
| Clear Labs, Inc. | 1 | $105.000 |
| Aperture Therapeutics, Inc. | 1 | $140.000 |
| Acrobat Genomics Inc. | 1 | $88.680 |
| Ridge Biotechnologies, Inc. | 1 | $90.000 |
| Acrocyte Therapeutics Inc. | 1 | $115.357 |
Nazivi delovnih mest
- Research Associate III3
- Senior Scientist, Analytical Development3
- Scientist I2
- Associate Scientist2
- Associate Engineer II, MSAT2
- Senior Scientist2
- Senior Scientist I1
- Group Leader, Formulation Development1
- Associate Scientist - II (Protein)1
- Group Leader, Drug Product1
- Associate Scientist II, Conjugation Development1
- Scientist II, Drug Discovery1
- Senior Scientist, Drug Product Analytics1
- Associate Engineer I1
- Associate Scientist I, Research1
Sponzorji H-1B v San Carlos, CA →
Plače so spodnja meja ponujene plače pri vsaki vlogi, pretvorjene v letni znesek; statistika uporablja samo potrjene vloge za polni delovni čas. LCA ni odobritev vizuma, ena LCA pa lahko pokriva več delovnih mest. Vir: U.S. Department of Labor, OFLC LCA Disclosure Data, davčna leta 2023–2026 (najnovejša odločitev 30. jun. 2026).